Navigation Links
Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call
Date:12/19/2011

PALO ALTO, Calif., Dec. 19, 2011 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) announced today that it will report results for the first quarter of fiscal year 2012 following the close of regular trading on Wednesday, January 25, 2012.  The news release will be followed by a teleconference available to all interested parties at 2:00 p.m. PT.  The news release and a link to the conference call webcast will be available on the company website at: www.varian.com/investor.  To access the teleconference call and replay:Teleconference:

Access from within the U.S. by dialing 1-866-700-0161, and from outside the U.S. by dialing 1-617-213-8832, and entering code 37675518. 

 Replay:

 

Access from within the U.S. by dialing 1-888-286-8010 and from outside the U.S. by dialing 1-617-801-6888, and entering code 39547714. The teleconference will be rebroadcast until 8:00 p.m. ET, Friday, January 27, 2012. 

 Webcast: 

Visit the company website at: www.varian.com/investor and click on the "Quarterly Conference Call" icon. Web conferences will be archived on the company website for a year.  For automatic "e-mail alerts" regarding Varian news and events, investors can subscribe on the company website: http://varian.investorroom.com/index.php?s=58.
For additional information contact Anne Rambo at 650-424-5834 or anne.rambo@varian.com

About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,700 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com or follow us on Twitter.

FOR INFORMATION CONTACT:
Spencer Sias, (650) 424-5782
Vice President, Corporate Communications
and Investor Relations
spencer.sias@varian.com


'/>"/>
SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
2. deCODE Announces Agreement With Pfizer to Search for Variants in the Human Genome That Confer Risk of Systemic Lupus Erythematosis
3. deCODE Genetics, in Collaboration with Academic Colleagues and Illumina, Discovers Two Rare Variants that Affect the Risk of Gout and Serum Uric Acid Levels
4. Selexis SA to Give Away Euro 25,000 SUREvariant Screening Service Project at BIO 2011
5. EntreMeds ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients
6. OVA1 Blood Test Detects Ovarian Cancer More Accurately Than Medically Accepted CA 125 Method for Evaluating Women with Ovarian Mass
7. Prostate cancer risk variant found to be in a functional DNA sequence linked with disease
8. Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency
9. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
10. ClearTrial to Demonstrate How a Top 20 Sponsor Achieved -1 Percent Cost Variance Across Their $130M Clinical Portfolio at Major Industry Conference
11. Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2019)... (PRWEB) , ... September 30, 2019 , ... ... materials science newsletter from Rigaku Corporation , is now available online on ... to X-ray based materials science, including X-ray diffraction, fluorescence and imaging, and presents ...
(Date:9/24/2019)... (PRWEB) , ... September 24, ... ... provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, ... a clinical-stage biopharmaceutical company focused on the development of therapies to treat ...
(Date:9/24/2019)... ... , ... In the past three years, the National Science Foundation (NSF) has ... School of Mines & Technology that expands human understanding of the microbial world. ... slimy and yet strong layer which is commonly known as a biofilm. , The ...
(Date:9/17/2019)... ... 2019 , ... Tucker, a Labrador retriever, was just a puppy when he ... and lame on his right hip and elbow. At one year of age, Tucker ... case the vet had seen.” He was prescribed pain medications, both oral and injectable, ...
Breaking Biology Technology:
(Date:10/3/2019)... ... October 02, 2019 , ... Personalized Stem Cells, ... patient in an FDA approved clinical trial for stem cell treatment of knee ... formation of the company as a subsidiary of VetStem Biopharma. , PSC CEO, Michael ...
(Date:9/30/2019)... ... September 30, 2019 , ... ... mesenchymal stem/stromal cell (hMSC) biomanufacturing systems, today announced it has received patent ... product formats (patent number AU 2015259373). This new patent adds intellectual property ...
(Date:9/25/2019)... ... , ... Deep Science Ventures (DSV), a new paradigm for applied ... of cancer research. , Deep Science Ventures was founded to create a better method ... from the start, both at the industry and biological level. , Through their ...
Breaking Biology News(10 mins):